collection
MENU ▼
Read by QxMD icon Read
search

Cardioncologia

shared collection
133 papers 25 to 100 followers
By Eduardo Roque Cardiologista com foco em cardiologia hospitalar e cuidados intensivos. Professor de clínica médica.
https://www.readbyqxmd.com/read/29457984/cardio-oncology-the-role-of-advanced-echocardiography-in-cancer-patients
#1
REVIEW
Lucia Venneri, Giacomo Zoppellaro, Rajdeep S Khattar
Cardio-oncology is a rapidly growing field aimed at improving the quality of care of cancer patients by preventing and monitoring cardiovascular complications resulting from cancer treatment. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential
role in the baseline assessment and serial follow-up of cardio-oncology patients. Areas covered: This review article discusses the role of cardiac imaging with a focus on advanced echocardiography for the detection and management of cancer therapy related cardiovascular complications, in particular, left ventricular dysfunction and heart failure...
April 2018: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/29494295/treating-cardiovascular-complications-of-radiotherapy-a-role-for-new-pharmacotherapies
#2
REVIEW
Nathalie Donis, Cécile Oury, Marie Moonen, Patrizio Lancellotti
Available data indicate that survivors of breast cancer and Hodgkin lymphoma who received mediastinal radiotherapy are at increased risk of developing radiation-induced cardiovascular diseases (RICVD) one or two decades after treatment. Although the risk with modern radiation treatment is likely to be lower in these patient groups, cardiotoxicity is still observed in a subset of patients. In addition, radiation-associated cardiovascular complications can, in the future, extend to other groups of cancer patients who are treated for tumors that are localized near the heart...
April 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29550304/is-there-added-value-of-the-third-imaging-dimension-in-cardio-oncology
#3
EDITORIAL
Paaladinesh Thavendiranathan
No abstract text is available yet for this article.
August 2018: JACC. Cardiovascular Imaging
https://www.readbyqxmd.com/read/29802472/biomarker-discovery-in-cardio-oncology
#4
REVIEW
Anita Vohra, Aarti Asnani
PURPOSE OF REVIEW: In this article, we review current and emerging approaches to biomarker discovery to facilitate early diagnosis of cancer therapy-associated cardiovascular toxicity. RECENT FINDINGS: Although small studies have demonstrated an association between established biomarkers of cardiac injury (troponins and brain natriuretic peptide) and acute or subacute cardiotoxicity, there is insufficient evidence to support their use in routine clinical care. Preclinical studies to define the molecular mechanisms of cardiotoxicity, as well as the use of unbiased "omics" techniques in small patient cohorts, have yielded promising candidate biomarkers that have the potential to enrich current risk stratification algorithms...
May 25, 2018: Current Cardiology Reports
https://www.readbyqxmd.com/read/29929621/cardio-oncology-for-gennext-a-missing-piece-of-the-training-puzzle
#5
EDITORIAL
Sarju Ganatra, Salim S Hayek
No abstract text is available yet for this article.
June 26, 2018: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/29194712/anthracycline-induced-acute-myocarditis-and-ventricular-fibrillation-arrest
#6
Vincent A Pallazola, Joseph C Murray, Munjid Al Harthy, Stefan L Zimmerman, Jonathan Webster, Lukasz P Gondek
No abstract text is available yet for this article.
March 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/28966326/bevacizumab-related-microvascular-angina-and-its-management-with-nicorandil
#7
Manami Katoh, Norihiko Takeda, Takahide Arimoto, Hajime Abe, Katsutoshi Oda, Yutaka Osuga, Tomoyuki Fujii, Issei Komuro
Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF)-A, is currently used to treat patients with ovarian or colon cancer. While several cardiovascular toxicities related to bevacizumab-containing regimens have been reported, the effect of bevacizumab on the coronary microcirculation has not been fully elucidated. Here we report a case of 54-year-old female patient who developed microvascular angina after a series of bevacizumab-containing chemotherapeutic regimen. The discontinuation of bevacizumab and nicorandil administration was effective in alleviating her chest discomfort and the ischemic changes on her ECG...
October 21, 2017: International Heart Journal
https://www.readbyqxmd.com/read/28824714/cardiac-metabolic-deregulation-induced-by-the-tyrosine-kinase-receptor-inhibitor-sunitinib-is-rescued-by-endothelin-receptor-antagonism
#8
Joevin Sourdon, Franck Lager, Thomas Viel, Daniel Balvay, Rebecca Moorhouse, Evangeline Bennana, Gilles Renault, Pierre-Louis Tharaux, Neeraj Dhaun, Bertrand Tavitian
The growing field of cardio-oncology addresses the side effects of cancer treatment on the cardiovascular system. Here, we explored the cardiotoxicity of the antiangiogenic therapy, sunitinib, in the mouse heart from a diagnostic and therapeutic perspective. We showed that sunitinib induces an anaerobic switch of cellular metabolism within the myocardium which is associated with the development of myocardial fibrosis and reduced left ventricular ejection fraction as demonstrated by echocardiography. The capacity of positron emission tomography with [18 F]fluorodeoxyglucose to detect the changes in cardiac metabolism caused by sunitinib was dependent on fasting status and duration of treatment...
2017: Theranostics
https://www.readbyqxmd.com/read/28862931/cardiovascular-adverse-events-in-patients-with-cancer-treated-with-bevacizumab-a-meta-analysis-of-more-than-20-000-patients
#9
REVIEW
Matthias Totzeck, Raluca Ileana Mincu, Tienush Rassaf
BACKGROUND: The monoclonal antibody bevacizumab effectively inhibits angiogenesis in several types of cancers by blocking vascular endothelial growth factor. However, life-threatening cardiovascular adverse effects could limit its use and may warrant specific follow-up strategies. METHODS AND RESULTS: We systematically searched MEDLINE, Cochrane, EMBASE, and Web of Science for randomized controlled trials published until November 2016 that assessed patients with cancer treated with or without bevacizumab in addition to standard chemotherapy...
August 10, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28797029/successful-use-of-equine-anti-thymocyte-globulin-atgam-for-fulminant-myocarditis-secondary-to-nivolumab-therapy
#10
Rebecca Y Tay, Elizabeth Blackley, Catriona McLean, Maggie Moore, Peter Bergin, Sanjeev Gill, Andrew Haydon
BACKGROUND: Immune-mediated myocarditis is an uncommon adverse effect of immune checkpoint inhibition and is associated with a high rate of mortality. METHODS: In this reported case, a 64-year-old woman with right temporo-parietal glioblastoma IDH-WT was treated with nivolumab, temozolomide and radiation therapy on a clinical trial. She developed malignant arrhythmias secondary to histologically confirmed severe immune-mediated myocarditis. She was treated with equine anti-thymocyte globulin (ATGAM) due to development of malignant arrhythmias refractory to high-dose corticosteroids...
September 26, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28803521/evaluation-of-direct-acting-oral-anticoagulant-use-in-patients-with-cancer
#11
Daphne O Davis, Kyle A Davis
PURPOSE: To evaluate the use of direct-acting oral anticoagulants in patients with cancer and venous thromboembolism (VTE) treated at Ochsner Medical Center with the intent of determining the efficacy and safety of these agents. METHODS: Patients were identified by a retrospective data extraction of patients treated at Ochsner Medical Center from January 1, 2013, through December 31, 2015. Patients were included for review if they were ≥18 years of age, with a confirmed diagnosis of VTE and active or history of cancer, and if they received dabigatran, apixaban, rivaroxaban, or edoxaban for at least 6 months...
January 1, 2017: Journal of Pharmacy Practice
https://www.readbyqxmd.com/read/28796051/changes-in-ischemia-modified-albumin-in-myocardial-toxicity-induced-by-anthracycline-and-docetaxel-chemotherapy
#12
Xiao-Dong Luan, Kai-Hua Zhao, Hong Hou, Yan-Hong Gai, Qi-Tang Wang, Qiang Mu, Yue Wan
This study aims to evaluate differences in myocardial toxicity induced by different chemotherapy regimens. Patients were divided into 2 groups: epirubicin (EPI) combined with cyclophosphamide (EC) group and docetaxel combined with cyclophosphamide (TC) group. Changes in electrocardiograph (ECG) and ischemia-modified albumin (IMA) were determined pre- and 1, 3, and 6 courses of postchemotherapy. After the first course of chemotherapy, there was no significant difference in ECG and abnormal IMA incidence rates between the TC groups and EC groups (P > ...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28708228/clinical-and-subclinical-cardiac-late-effects-in-pediatric-hodgkin-s-lymphoma-survivors
#13
Carlo Materazzo, Maura Massimino, Elisabetta Schiavello, Marta Podda, Lorenza Gandola, Graziella Cefalo, Serena Catania, Cristina Meazza, Ivan Moschetti, Monica Terenziani
PURPOSE: Cardiac late effects are responsible for a significant burden of mortality and morbidity among pediatric Hodgkin's lymphoma (HL) survivors (HLS). The aim of our study was to assess clinical and subclinical cardiac sequelae in a cohort of childhood HLS treated in the 1980s with doxorubicin, bleomycin, vinblastine, and dacarbazine (the ABVD regimen) and limited-field radiotherapy (RT). METHODS: We retrospectively examined a series of HLS treated from 1979 to 1989...
November 23, 2017: Tumori
https://www.readbyqxmd.com/read/28410144/cardiotoxicity-in-oncology-and-coronary-microcirculation-future-challenges-in-theranostics
#14
REVIEW
Giovanni Peretto, Davide Lazzeroni, Carmem L Sartorio, Paolo G Camici
Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28425056/ischemic-heart-disease-special-considerations-in-cardio-oncology
#15
REVIEW
Dana Elena Giza, Fernando Boccalandro, Juan Lopez-Mattei, Gloria Iliescu, Kaveh Karimzad, Peter Kim, Cezar Iliescu
The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease...
May 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28320853/cardio-oncology-vascular-endothelial-growth-factor-inhibitors-salt-and-macrophages-a-complicated-interaction
#16
EDITORIAL
Javid Moslehi, Arvind K Pandey, Nirmanmoh Bhatia
No abstract text is available yet for this article.
May 2017: Hypertension
https://www.readbyqxmd.com/read/28330611/rationale-for-cardio-oncology-units
#17
REVIEW
Lara F Nhola, Hector R Villarraga
With the rapidly rising number of patients surviving cancer, often in the setting of new or pre-existing cardiovascular disease and risk factors, a need has arisen for a specialty within the realm of cardiovascular care that can evaluate and manage these patients along with our colleagues in oncology and hematology. By the same token, all health care providers involved in the care of cancer patients with heart disease must be fully aware of the impact of adverse cardiovascular effects on the survival of these patients...
July 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28365180/practices-in-management-of-cancer-treatment-related-cardiovascular-toxicity-a-cardio-oncology-survey
#18
Ludovic Jovenaux, Jennifer Cautela, Noemie Resseguier, Michele Pibarot, Myriam Taouqi, Morgane Orabona, Johan Pinto, Michael Peyrol, Jeremie Barraud, Marc Laine, Laurent Bonello, Franck Paganelli, Fabrice Barlesi, Franck Thuny
BACKGROUND: Cardiovascular toxicity has become a challenging issue during cancer therapy. Nonetheless, there is a lack of consensual guidelines for their management. We aimed to determine the current practices of oncologists regarding cardiovascular toxicity related to anthracyclines, trastuzumab and angiogenic inhibitors and to gather their opinions on the development of cardio-oncology programs. METHODS: A cross-sectional declarative study was submitted to French oncologists in the form of an individual, structured questionnaire...
August 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28279420/how-to-develop-a-cardio-oncology-clinic
#19
REVIEW
David Snipelisky, Jae Yoon Park, Amir Lerman, Sharon Mulvagh, Grace Lin, Naveen Pereira, Martin Rodriguez-Porcel, Hector R Villarraga, Joerg Herrmann
Cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. As a consequence, interactions with cardiovascular disease specialists have intensified to the point of the development of a new discipline termed cardio-oncology. As an additional consequence, so-called cardio-oncology clinics have emerged, in most cases staffed by cardiologists with an interest in the field. This article addresses this gap and summarizes key points in the development of a cardio-oncology clinic...
April 2017: Heart Failure Clinics
https://www.readbyqxmd.com/read/28279421/how-to-develop-a-cardio-oncology-fellowship
#20
REVIEW
Michelle N Johnson, Richard Steingart, Joseph Carver
Management of cardiovascular disease in patients with cancer and cancer survivors requires particular clinical expertise and skills that are central to cardio-oncology. The areas of knowledge required include specific cardiovascular complications directly related to oncologic therapies and the impact of cancer and its therapies on existing or potential cardiovascular comorbidities. Many cancer therapeutics have potential cardiotoxicity. The conversion of many cancers to chronic conditions, rather than fatal diseases, has produced a population of patients with cancer at high risk for cardiovascular diseases that require specialized knowledge of treating physicians...
April 2017: Heart Failure Clinics
label_collection
label_collection
4812
1
2
2017-03-17 01:06:35
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"